[1] Alexander KS, Zakai NA, Lidofsky SD, et al. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLoS One, 2018,13:e0194153. [2] Feng R , Li Y , Wang C , et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract, 2014,106:88-94. [3] Ebrahimi S , Gargari BP , Izadi A , et al. The effects of Ramadan fasting on serum concentrations of vaspin and omentin-1 in patients with nonalcoholic fatty liver disease. Eur J Integr Med,2018, 19:110-114. [4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2011, 18:167-170. [5] Byrne CD , Targher G . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia, 2017,60:1218-1222. [6] Jung U , Choi MS . Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. Int J Mol Sci, 2014, 15:6184-6223. [7] Zhong X , Li X , Liu F , et al. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun, 2012, 425:401-406. [8] Yilmaz Y , Yonal O , Kurt R , et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol, 2011, 54:S349-S350. [9] Feng R , Li Y , Wang C , et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract, 2014, 106:88-94. [10] Farhangi MA, Alipour B, Jafarvand E, et al. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch Med Res, 2014, 45:589-595. [11] Salama HM , Ashraf G , Motawie AA , et al. Adipokines Vaspin and Visfatin in Obese Children. Open Access Maced J Med Sci, 2015, 3:563-566. [12] Polyzos SA , Kountouras J , Polymerou V , et al. Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease. Ann Hepatol, 2016, 15:705. [13] Yamawaki H , Kuramoto J , Kameshima S , et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun, 2011, 408:339-343. |